These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34979242)

  • 1. Insulin Growth Factor Phenotypes in Heart Failure With Preserved Ejection Fraction, an INSPIRE Registry and CATHGEN Study.
    Haddad F; Ataam JA; Amsallem M; Cauwenberghs N; Kuznetsova T; Rosenberg-Hasson Y; Zamanian RT; Karakikes I; Horne BD; Muhlestein JB; Kwee L; Shah S; Maecker H; Knight S; Knowlton K
    J Card Fail; 2022 Jun; 28(6):935-946. PubMed ID: 34979242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction.
    Barroso MC; Kramer F; Greene SJ; Scheyer D; Köhler T; Karoff M; Seyfarth M; Gheorghiade M; Dinh W
    BMC Cardiovasc Disord; 2016 Oct; 16(1):199. PubMed ID: 27769173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HFpEF and HFrEF Display Different Phenotypes as Assessed by IGF-1 and IGFBP-1.
    Faxén UL; Hage C; Benson L; Zabarovskaja S; Andreasson A; Donal E; Daubert JC; Linde C; Brismar K; Lund LH
    J Card Fail; 2017 Apr; 23(4):293-303. PubMed ID: 27327968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Value of IGF-1 and IGFBP-1 in Patients With Heart Failure With Reduced, Mid-range, and Preserved Ejection Fraction.
    Guo S; Gong M; Tse G; Li G; Chen KY; Liu T
    Front Cardiovasc Med; 2021; 8():772105. PubMed ID: 35127852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma tumour and metabolism related biomarkers AMBP, LPL and Glyoxalase I differentiate heart failure with preserved ejection fraction with pulmonary hypertension from pulmonary arterial hypertension.
    Ahmed S; Ahmed A; Rådegran G
    Int J Cardiol; 2021 Dec; 345():68-76. PubMed ID: 34710494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
    Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
    Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth differentiation factor 15 as mortality predictor in heart failure patients with non-reduced ejection fraction.
    Mendez Fernandez AB; Ferrero-Gregori A; Garcia-Osuna A; Mirabet-Perez S; Pirla-Buxo MJ; Cinca-Cuscullola J; Ordonez-Llanos J; Roig Minguell E
    ESC Heart Fail; 2020 Oct; 7(5):2223-2229. PubMed ID: 32589369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction.
    Hage C; Bjerre M; Frystyk J; Gu HF; Brismar K; Donal E; Daubert JC; Linde C; Lund LH
    Am J Cardiol; 2018 Jun; 121(12):1558-1566. PubMed ID: 29622288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocardial expression of somatotropic axis, adrenergic signalling, and calcium handling genes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction.
    D'Assante R; Arcopinto M; Rengo G; Salzano A; Walser M; Gambino G; Monti MG; Bencivenga L; Marra AM; Åberg DN; De Vincentiis C; Ballotta A; Bossone E; Isgaard J; Cittadini A
    ESC Heart Fail; 2021 Apr; 8(2):1681-1686. PubMed ID: 33512777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular magnetic resonance predicts all-cause mortality in pulmonary hypertension associated with heart failure with preserved ejection fraction.
    Garg P; Lewis RA; Johns CS; Swift AJ; Capener D; Rajaram S; Thompson AAR; Condliffe R; Elliot CA; Charalampopoulos A; Hameed AG; Rothman A; Wild JM; Kiely DG
    Int J Cardiovasc Imaging; 2021 Oct; 37(10):3019-3025. PubMed ID: 33978936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
    Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
    J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RV Contractile Function and its Coupling to Pulmonary Circulation in Heart Failure With Preserved Ejection Fraction: Stratification of Clinical Phenotypes and Outcomes.
    Guazzi M; Dixon D; Labate V; Beussink-Nelson L; Bandera F; Cuttica MJ; Shah SJ
    JACC Cardiovasc Imaging; 2017 Oct; 10(10 Pt B):1211-1221. PubMed ID: 28412423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction.
    Vanderpool RR; Saul M; Nouraie M; Gladwin MT; Simon MA
    JAMA Cardiol; 2018 Apr; 3(4):298-306. PubMed ID: 29541759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
    Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction.
    Salah K; Stienen S; Pinto YM; Eurlings LW; Metra M; Bayes-Genis A; Verdiani V; Tijssen JGP; Kok WE
    Heart; 2019 Aug; 105(15):1182-1189. PubMed ID: 30962192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Biomarkers and Unique Pathways in Different Phenotypes of Heart Failure with Preserved Ejection Fraction.
    Chen H; Tesic M; Nikolic VN; Pavlovic M; Vucic RM; Spasic A; Jovanovic H; Jovanovic I; Town SEL; Padula MP; McClements L
    Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register.
    Eriksson B; Wändell P; Dahlström U; Näsman P; Lund LH; Edner M
    Scand J Prim Health Care; 2019 Dec; 37(4):434-443. PubMed ID: 31724475
    [No Abstract]   [Full Text] [Related]  

  • 18. CT-IGFBP-4 as a novel prognostic biomarker in acute heart failure.
    Konev AA; Kharitonov AV; Rozov FN; Altshuler EP; Serebryanaya DV; Lassus J; Harjola VP; Katrukha AG; Postnikov AB
    ESC Heart Fail; 2020 Apr; 7(2):434-444. PubMed ID: 31967738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obese-Inflammatory Phenotypes in Heart Failure With Preserved Ejection Fraction.
    Sabbah MS; Fayyaz AU; de Denus S; Felker GM; Borlaug BA; Dasari S; Carter RE; Redfield MM
    Circ Heart Fail; 2020 Aug; 13(8):e006414. PubMed ID: 32809874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization.
    Nikolova AP; Hitzeman TC; Baum R; Caldaruse AM; Agvanian S; Xie Y; Geft DR; Chang DH; Moriguchi JD; Hage A; Azarbal B; Czer LS; Kittleson MM; Patel JK; Wu AHB; Kobashigawa JA; Hamilton M; Hong T; Shaw RM
    JAMA Cardiol; 2018 Dec; 3(12):1206-1210. PubMed ID: 30383171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.